NO20020253L - Katalytiske anti-faktor VIII allo-antistoffer - Google Patents

Katalytiske anti-faktor VIII allo-antistoffer

Info

Publication number
NO20020253L
NO20020253L NO20020253A NO20020253A NO20020253L NO 20020253 L NO20020253 L NO 20020253L NO 20020253 A NO20020253 A NO 20020253A NO 20020253 A NO20020253 A NO 20020253A NO 20020253 L NO20020253 L NO 20020253L
Authority
NO
Norway
Prior art keywords
factor viii
catalytic anti
viii allo
antibodies
allo antibodies
Prior art date
Application number
NO20020253A
Other languages
English (en)
Norwegian (no)
Other versions
NO20020253D0 (no
Inventor
Srinivas Kaveri
Sebastien Lacroix-Desmazes
Michel Kazatchkine
Original Assignee
Bayer Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma filed Critical Bayer Pharma
Publication of NO20020253D0 publication Critical patent/NO20020253D0/no
Publication of NO20020253L publication Critical patent/NO20020253L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20020253A 1999-07-21 2002-01-17 Katalytiske anti-faktor VIII allo-antistoffer NO20020253L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99401841A EP1074842A1 (en) 1999-07-21 1999-07-21 Catalytic anti-factor VIII allo-antibodies
PCT/EP2000/006870 WO2001007918A1 (en) 1999-07-21 2000-07-18 Catalytic anti-factor viii allo-antibodies

Publications (2)

Publication Number Publication Date
NO20020253D0 NO20020253D0 (no) 2002-01-17
NO20020253L true NO20020253L (no) 2002-03-13

Family

ID=8242069

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020253A NO20020253L (no) 1999-07-21 2002-01-17 Katalytiske anti-faktor VIII allo-antistoffer

Country Status (24)

Country Link
US (2) US7507540B1 (pl)
EP (2) EP1074842A1 (pl)
JP (2) JP2003505434A (pl)
KR (1) KR100788435B1 (pl)
CN (1) CN1229646C (pl)
AU (1) AU777615B2 (pl)
BR (1) BR0012613A (pl)
CA (1) CA2379818A1 (pl)
CZ (1) CZ2002248A3 (pl)
EE (1) EE200200034A (pl)
HK (1) HK1044372A1 (pl)
HU (1) HUP0201941A3 (pl)
IL (1) IL147700A0 (pl)
IS (1) IS6238A (pl)
MX (1) MXPA02000752A (pl)
NO (1) NO20020253L (pl)
NZ (1) NZ516702A (pl)
PL (1) PL353739A1 (pl)
RU (1) RU2258935C2 (pl)
SK (1) SK862002A3 (pl)
TR (1) TR200200340T2 (pl)
UA (1) UA75867C2 (pl)
WO (1) WO2001007918A1 (pl)
ZA (1) ZA200200351B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI452136B (zh) 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
FR2969761A1 (fr) * 2010-12-22 2012-06-29 Lfb Biotechnologies Procede de dosage d'anticorps diriges contre le facteur viii
TWI701435B (zh) * 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
CR20180554A (es) 2016-04-28 2019-01-10 Chugai Pharmaceutical Co Ltd Preparaciones que contienen anticuerpos
CN110461358A (zh) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
CN119161488A (zh) 2017-11-01 2024-12-20 中外制药株式会社 具有降低的生物活性的抗体变体和同种型

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744446A (en) * 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
WO1994011013A1 (en) * 1992-11-13 1994-05-26 Duke University Chimeric blood coagulation proteins
US5910481A (en) * 1995-11-13 1999-06-08 Immuno Ag Hybrid proteins with modified activity
US5744326A (en) * 1996-03-11 1998-04-28 The Immune Response Corporation Use of viral CIS-acting post-transcriptional regulatory sequences to increase expression of intronless genes containing near-consensus splice sites

Also Published As

Publication number Publication date
ZA200200351B (en) 2003-03-26
KR20020042618A (ko) 2002-06-05
NO20020253D0 (no) 2002-01-17
AU6824500A (en) 2001-02-13
UA75867C2 (en) 2006-06-15
JP2009292823A (ja) 2009-12-17
KR100788435B1 (ko) 2007-12-24
TR200200340T2 (tr) 2003-01-21
RU2258935C2 (ru) 2005-08-20
HUP0201941A3 (en) 2005-01-28
CA2379818A1 (en) 2001-02-01
PL353739A1 (pl) 2003-12-01
WO2001007918A1 (en) 2001-02-01
US20090208512A1 (en) 2009-08-20
BR0012613A (pt) 2002-04-09
JP2003505434A (ja) 2003-02-12
IL147700A0 (en) 2002-08-14
IS6238A (is) 2002-01-16
HK1044372A1 (zh) 2002-10-18
AU777615B2 (en) 2004-10-21
US7507540B1 (en) 2009-03-24
HUP0201941A2 (en) 2002-10-28
CN1361865A (zh) 2002-07-31
MXPA02000752A (es) 2003-07-14
SK862002A3 (en) 2002-06-04
NZ516702A (en) 2003-10-31
CZ2002248A3 (cs) 2002-07-17
EE200200034A (et) 2003-06-16
EP1196782A1 (en) 2002-04-17
EP1074842A1 (en) 2001-02-07
CN1229646C (zh) 2005-11-30

Similar Documents

Publication Publication Date Title
NO2022060I1 (no) Aflibercept
ID28627A (id) Katalis
NL300939I2 (nl) Benralizumab
NO20014238D0 (no) Spesifikasjon for ABAP-kode konverter
NO20022615L (no) Koboltkatalysatorer
DK1248675T3 (da) Katalytisk reaktor
DE60039945D1 (de) Kraftfahrzeugstruktur
DE69902548D1 (de) Katalysatoraktivatorverbindung
DE60012103D1 (de) Fahrzeugbaustruktur
DE60015683D1 (de) Fahrzeugbaustruktur
ID26707A (id) Katalisator untuk produksi-olefin dan metode produksi-olefin
DE60025098D1 (de) Fahrzeugbaustruktur
NO981126D0 (no) Forbedret katalysatorbærer
DE60002566D1 (de) Katalysatorsysteme
ID29169A (id) Penguatan rangka kendaraan
ID26688A (id) Katalis-katalis unggun tetap
NO20021020D0 (no) Kjöretöy
DE50009579D1 (de) Kraftfahrzeug-Türschliesssystem
DE60003901D1 (de) Fahrzeug
ITMI991348A0 (it) Procedimento migliorato di fischer-tropsch
DE60014260D1 (de) Klammer
NO20020253L (no) Katalytiske anti-faktor VIII allo-antistoffer
DE60142845D1 (de) Katalysatorträger
FI20001817L (fi) Katalyyttisäiliö
DE60041737D1 (de) Fahrzeug

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application